Ipsen News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

27.06.23	IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2023 (GlobeNewswire)
20.06.23	IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2023 (GlobeNewswire)
14.06.23	Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma (GlobeNewswire)
13.06.23	U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome (GlobeNewswire)
13.06.23	IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2023 (GlobeNewswire)
12.06.23	Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023 (GlobeNewswire)
09.06.23	Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
06.06.23	IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023 (GlobeNewswire)
01.06.23	Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan (GlobeNewswire)
31.05.23	Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 (GlobeNewswire)
31.05.23	Ipsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023 (GlobeNewswire)
26.05.23	Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U. (GlobeNewswire)
17.05.23	Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases (GlobeNewswire)
10.05.23	Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023 (GlobeNewswire)
10.05.23	Ipsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting (GlobeNewswire)
27.04.23	Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance (GlobeNewswire)
24.04.23	Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs (GlobeNewswire)
11.04.23	Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
06.04.23	Ipsen S.A. publishes its 2022 Universal registration document (GlobeNewswire)
16.03.23	Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP (GlobeNewswire)
10.03.23	Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
02.03.23	Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio (GlobeNewswire)
22.02.23	Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 (GlobeNewswire)
15.02.23	Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs (GlobeNewswire)
13.02.23	Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma (GlobeNewswire)
27.01.23	Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. (Businesswire)
20.01.23	Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI (Businesswire)
09.01.23	Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases (Businesswire)
23.12.22	Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (Businesswire)
09.11.22	Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Businesswire)
27.10.22	Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance (Businesswire)
25.10.22	Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting (Businesswire)
12.08.22	Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology (Businesswire)
05.08.22	Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 (Businesswire)
03.08.22	Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer (Businesswire)
01.08.22	Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic (Businesswire)
29.06.22	Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission (Businesswire)
27.06.22	Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology (Businesswire)
09.06.22	Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury (Businesswire)
01.06.22	Ipsen Initiates a Share Buy-Back Program to Cover Its Employee Free Share-Allocation Plan (Businesswire)
26.05.22	Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer (Businesswire)
03.05.22	Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer (Businesswire)
27.04.22	Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022 (Businesswire)
25.03.22	Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer (Businesswire)
16.03.22	Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience (Businesswire)
08.03.22	Ipsen: New Patient-Reported Data Demonstrated High Satisfaction Levels and Fewer Patients Reporting Injection-site Pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide) (Businesswire)
15.02.22	Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial (Businesswire)
24.01.22	Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva (Businesswire)
21.01.22	Ipsen Nominates Karen Witts as New Independent Board Member (Businesswire)
17.12.21	Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	536.20	0.98 %	K V
Part Grp Hldg	1’255.50	0.36 %	K V
Roche Hldg G	252.20	0.32 %	K V
Alcon	77.84	0.28 %	K V
Novartis	92.12	0.21 %	K V
ABB	49.20	-0.69 %	K V
CieFinRichemont	121.50	-0.69 %	K V
UBS Group	27.52	-0.86 %	K V
Sika	225.90	-1.18 %	K V
Logitech Intl	70.46	-2.11 %	K V